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Diabetes mellitus is associated with natriuresis, whereas
estrogen has been shown to be renoprotective in diabetic
nephropathy and may independently regulate renal sodium
reabsorption. The aim of this study was to determine the
effects of 17-b estradiol (E2) replacement to diabetic,
ovariectomized (OVX) female rats on the expression of major
renal sodium transporters. Female, Sprague–Dawley rats
(210 g) were randomized into four groups: (1) OVX;
(2) OVXþ E2; (3) diabeticþovariectomized (DþOVX); and
(4) diabeticþ ovariectomizedþ estrogen (DþOVXþ E2).
Diabetes was induced by a single intraperitoneal injection of
streptozotocin (55 mg/kg . body weight (bw)). Rats received
phytoestrogen-free diet and water ad libitum for 12 weeks.
E2 attenuated hyperglycemia, hyperalbuminuria, and
hyperaldosteronism in D rats, as well as the diabetes-induced
changes in renal protein abundances for the
bumetanide-sensitive Na–K–2Cl cotransporter (NKCC2), and
the a- and b-subunits of the epithelial sodium channel
(ENaC), that is, E2 decreased NKCC2, but increased a- and
b-ENaC abundances. In nondiabetic rats, E2 decreased plasma
Kþ and increased urine Kþ /Naþ ratio, as well as decreased
the abundance of NKCC2, b-ENaC, and a-1-Na–K–adenosine
triphosphate (ATP)ase in the outer medulla. Finally, the
diabetic, E2 rats had measurably lower final circulating levels
of E2 than the nondiabetic E2 rats, despite an identical
replacement protocol, suggesting a shorter biological
half-life of E2 with diabetes. Therefore, E2 attenuated diabetes
and preserved renal sodium handling and related transporter
expression levels. In addition, E2 had diabetes-independent
effects on renal electrolyte handling and associated proteins.
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Uncontrolled diabetes mellitus (DM) is associated with a
natriuresis that, if not renally compensated for, can lead to
volume depletion. Previously, we1 showed an increase in
several key distal sodium transport proteins, that is, the
bumetanide-sensitive Na–K–2Cl cotransporter (NKCC2), the
thiazide-sensitive Na–Cl cotransporter (NCC), and the a-, b-,
and g-subunits of the epithelial sodium channel (ENaC) after
only 4 days of streptozotocin-induced type I diabetes in
young, male rats. Furthermore, Kim et al.2–4 have shown
increases in urea transporters, aquaporins, and sodium-
coupled cotransporters in more chronic studies (up to 20
days). However, the ability to compensate longer term for
type I DM with regard to changes in sodium transporters has
not been adequately studied.
In addition, we have demonstrated that chronic type II
DM in obese Zucker rats results in marked downregulation of
the abundance of several key sodium transporters and
channel subunits, including the bumetanide-sensitive
NKCC2 of the thick ascending limb and the sodium
hydrogen exchanger (NHE3).5 This downregulation was
most severe in the medullary portion of the kidney and
was negatively correlated to creatinine clearance.
Recent studies,6,7 including our own,6 suggest that
estrogen and its major metabolites may protect the diabetic
kidney from extracellular matrix accumulation, tubulointer-
stitial fibrosis, glomerulopathy, and nephropathy. This may
be partly a result of the ability of estrogen to blunt signaling
via the renin–angiotensin–aldosterone system. 17-b Estradiol
(E2) replacement to ovariectomized (OVX) rats downregu-
lates angiotensin II type 1 receptor binding in the adrenal
gland8,9 and aldosterone secretion10 in rats. Nevertheless, E2
replacement to OVX female rats has also been shown to
increase the apical plasma membrane residency of NCC, an
aldosterone-regulated protein.11 Therefore, its effects on the
renin–angiotensin–aldosterone system, especially with regard
to the regulation of renal sodium reabsorptive proteins, are
clearly complex.
Therefore, in these studies, we sought to determine
whether E2 replacement to diabetic OVX female rats would
be protective, with regard to the severity of the diabetes itself
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as well as with regard to regulation of renal sodium balance,
and the abundances of the major renal sodium transport
proteins. These proteins include (1) the NHE3 of the
proximal tubule and thick ascending limb apical membrane,
(2) the sodium phosphate cotransporter (NaPi-2), (3) the
bumetanide-sensitive NKCC2, (4) the thiazide-sensitive
Na–Cl cotransporter (NCC), the (5) a-, (6) b-, and (7)
g-subunits of the ENaC, and (8) the a-1 subunit of the
Na–K–ATPase pump.
RESULTS
Physiology
E2 replacement to the diabetic rats normalized bw gain
(Figure 1a). There were no significant differences between the
OVX, OVXþ E2, and the DþOVXþ E2 groups, at any of the
weeks, except for the final week, where the OVX were
significantly heavier than DþOVXþ E2. The OVX group
was gaining weight at a faster rate, at the end of the study,
than either of the E2-replete groups. The DþOVX group was
significantly lighter than the other three groups after 5 weeks,
at which time the weight of these animals basically plateaued.
Individual rat blood glucose levels, at the time of
euthanization, are graphed in Figure 1b. E2 replacement to
diabetic rats attenuated the hyperglycemia. Several diabetic
rats had glucose levels above 28 mmol/l, which were out of
range of our glucometer; thus, for statistical purposes, rats
were assigned into a category based on their glucose level,
that is, (1) normal, o6.7 mmol/l; (2) moderately high,
6.7–16.7; (3) high (but measurable), 16.7–28; and (4) high
(out of range), 428. The dashed lines in the figure show how
many rats of each treatment fell into each category. Statistical
analysis of the category assignations by analysis of variance
(ANOVA) on ‘ranks’ or categories revealed that the DþOVX
group had significantly higher final blood glucose levels
(Po0.05) than the other three groups.
Urine volume was increased in diabetic rats, as expected
(Figure 2a). However, E2 replacement markedly suppressed
this increase, indicative of less osmotic loss of water due to
glucosuria. In addition, a reduction in urinary albumin
excretion was observed in diabetic rats replaced with E2
(Figure 2b).
Estradiol was below the level of detection in most of the
OVX rats, as well as in two of six of the DþOVXþ E2 rats
(Figure 2c). Thus, as with blood glucose, data were cate-
gorized into levels 1–4 depending on whether estrogen was
(1) undetectable; (2) o73; (3) 73–184; or (4) 4184 pmol/l,
and ANOVA on ranks was performed. E2 replacement
caused a significant increase in the circulating level between
OVX and OVXþ E2 groups, but not between the DþOVX320
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Figure 1 | Bw over time and blood glucose levels (n¼ 6 rats/
treatment). (a) Weekly mean bw. (b) Final blood glucose levels for all
rats in the study plotted individually and divided into diabetic
severity groups for rank analysis. *Next to or above a symbol
indicates that the ‘starred’ group is significantly different (Po0.05)
from the OVX group; t indicates a significant difference from the
OVXþ E2 group, and l from the DþOVX group, as determined by
Tukey’s multiple comparisons test following one-way ANOVA. E2
replacement to diabetic rats helped them to maintain bw. Glucose
levels were lower in estrogen-replaced, diabetic rats (Kruskal–Wallis,
P-value o0.05).
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Figure 2 | Urine volume and albumin excretion over time and
plasma estradiol levels (n¼ 6 rats/treatment). (a) Mean urine
volume and (b) albumin excretion in 24-h urine collections obtained
at 3, 6, 9, and 12 weeks into the study. (c) Final plasma estradiol levels
plotted individually and divided into levels for rank analysis. *Above a
symbol indicates that the ‘starred’ group is significantly different
(Po0.05) from the OVX group; t indicates a significant difference
from the OVXþ E2 group, and l from the DþOVX group, as
determined by Tukey’s multiple comparisons test following one-way
ANOVA. E2 replacement reduced urine volume and albumin excretion
in diabetic rats. Estradiol concentrations were significantly increased
in the OVXþ E2 group relative to the OVX group in nondiabetic, but
not diabetic rats (Kruskal–Wallis, P-value o0.05).
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and DþOVXþ E2 groups. Thus, not only did E2 replace-
ment attenuate the diabetes, but also the diabetes seemed to
reduce the circulating estradiol levels despite identical
replacement protocols.
Plasma fructosamine levels were not significantly different
between groups, likely due to high variability in the diabetic
groups, although there was a trend for them to be higher in
the DþOVX group (Table 1). Plasma creatinine levels were
reduced by estrogen and urine creatinine was increased in the
diabetic rats. However, there were no significant differences
in creatinine clearance, an index of glomerular filtration rate,
among groups. Urine osmolality, like fructosamine, was
highly variable and tended to be decreased, but not
significantly different, in the DþOVX group. Plasma
arginine vasopressin levels were significantly increased in
the diabetic rats, and reduced by E2 replacement.
Similarly, plasma aldosterone levels were increased
significantly (2–3-fold) by diabetes and reduced by E2
(Table 2). However, urinary Kþ to Naþ ratio (a putative
measure of aldosterone activity) was decreased by diabetes
and increased by E2. Renin activity was not different between
groups. Plasma sodium levels were decreased significantly by
diabetes and returned to near normality by E2. Diabetes, in
general, reduced the level of plasma potassium. In addition, in
the nondiabetic groups, plasma potassium was significantly
reduced by E2 replacement, so that OVX rats had higher levels
of plasma Kþ than did the other three groups. Finally,
fractional excretion of sodium was increased in diabetic rats
and this increase was attenuated in E2-treated rats.
Immunoblotting
A summary of all whole-kidney homogenate immunoblots is
given in Table 3. Immunoblotting of the whole kidney is
carried out to get a general picture of whole-kidney
regulation of any particular protein, whereas immunoblot-
ting of the cortex, outer, and inner medulla is carried out to
Table 1 | Renal function and general physiologya
Group
Plasma
fructosamine
(lmol/l)
Plasma
creatinine
(lmol/l)
Urine creatinineb
(lmol/day/
kg . bw)
Creatinine
clearanceb
(ml/min/kg . bw)
Urine
osmolalityb
(mOsm/kg . H2O)
Plasma
vasopressin
(pmol/l)
OVX 213771 39.173.1 239717 4.3670.40 15527620 6.970.7
OVX+E2 215745 22.672.6* 186732 5.9570.79 19667753 5.671
D+OVX 6567212 39.675.6 267714 5.1470.78 348767 17.874c,*
D+OVX+E2 2597142 33.573.4 250714 5.4870.65 11137442 7.672
Factor Results of two-way ANOVA (P-values)
Diabetes 0.097 0.141 0.036 0.83 0.38 0.01
Estrogen 0.17 0.007 0.1 0.17 0.053 0.021
Interaction 0.17 0.176 0.39 0.36 0.089 0.068
ANOVA, analysis of variance; D, diabetic; E2, estrogen; OVX, ovariectomized.
Numbers in bold indicate significantly different (Po0.05) P-values for two-way ANOVA.
aMean7s.e.m.; n=6 for both groups.
bAt 12 weeks.
cSignificantly different from OVX+E2 as determined by one-way ANOVA followed by Tukey’s multiple-comparisons test.
*Significantly different (Po0.05) from OVX.
Table 2 | Electrolyte regulationa
Group
Plasma aldosterone
(nmol/l)
Plasma renin
activityb (ng/ml/h)
Urine K+/Na+
ratioc
Plasma Na+
(mmol/l)
Plasma K+
(mmol/l)
Fractional excretion
of sodiumc,d (%)
OVX 0.8570.16 72710 1.6470.11 14071 6.970.3 0.2970.07
OVX+E2 0.4970.13 70717 2.6670.24* 14071 5.870.2* 0.2470.06
D+OVX 2.3270.43*,e 47714 1.4970.18e 12872*,e 5.870.1* 1.3670.03*,e
D+OVX+E2 1.0970.37
f 53714 1.7070.21e 13773 5.470.2* 0.7670.03
Factor Results of two-way ANOVA (P-values)
Diabetes 0.003 0.31 0.004 0.01 0.002 0.002
Estrogen 0.016 0.54 0.008 0.021 o0.001 0.15
Interaction 0.16 0.45 0.045 0.068 0.075 0.23
ANOVA, analysis of variance; D, diabetic; E2, estrogen; OVX, ovariectomized.
Numbers in bold indicate significantly different (Po0.05) P-values for two-way ANOVA.
aMean7s.e.m.; n=6 for both groups.
bGenerated angiotensin I.
cAt 12 weeks.
dCalculated as ((UNa*Pcreat)/(Ucreat*PNa))*100.
*Significantly different (Po0.05) from OVX.
eSignificantly different from OVX+E2.
fSignificantly different from D+OVX as determined by one-way ANOVA followed by Tukey’s multiple-comparisons test.
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determine whether there may also be regional differences in
the regulation of that protein. The cortex, outer and inner
medulla blots (when appropriate) are presented in Figures
3–6. NHE3 was modestly, but significantly, increased by
diabetes in whole kidney (Table 3). In the cortex, the increase
in NHE3 was only observed in the DþOVX group (Figure 3a
and b). In the outer medulla, there was likewise a trend for
diabetes to increase NHE3 (P¼ 0.057, nonsignificant), but
there were no differences between individual pairs of means
by one-way ANOVA (Figure 3c). NaPi-2 protein in the cortex
was significantly decreased by diabetes (Figure 3a and d).
In the outer medulla (Figure 4a and c) and in the whole
kidney (Table 3), diabetes increased the abundance of the
bumetanide-sensitive NKCC2. The outer medullary increase
was reduced by E2. The trend was the same in the cortex
(Figure 4a and b); however, it did not reach significance.
Similarly, the abundance of the thiazide-sensitive NCC
was reduced by E2, but only in nondiabetic rats (Table 3,
Table 3 | Whole-kidney homogenate immunoblotting band density summary (% OVX)a
Group NHE3 NaPi-2 NKCC2 NCC a-ENaC b-ENaC c-ENaC (85 kDa) c-ENaC (70 kDa) a-1 Na–K–ATPase
OVX 10074 100711 10078 10074 10074 10074 10073 10078 100710
OVX+E2 11171* 64719 8678 7175* 10672 9977 10275 8676 101712
D+OVX 11874* 65714 123711 5472*,b 7776*,b 6079*,b 10178 9176 145722
D+OVX+E2 12272* 6379 118714 5174*
,b 10578c 9176c 13279*,b,c 98713 166716*,b
Factor Results of two-way ANOVA (P-values)
Diabetes o0.001 0.21 0.017 o0.001 0.039 0.002 0.034 0.87 0.003
Estrogen 0.014 0.18 0.40 o0.001 0.006 0.042 0.019 0.69 0.51
Interaction 0.211 0.24 0.67 0.003 0.055 0.028 0.042 0.26 0.54
ANOVA, analysis of variance; D, diabetic; E2, estrogen; NaPi-2, sodium phosphate cotransporter; NCC, Na–Cl cotransporter; NHE3, sodium hydrogen exchanger; NKCC2,
Na–K–2Cl cotransporter; OVX, ovariectomized.
Numbers in bold indicate significantly different P-values for two-way ANOVA.
aMean7s.e.m., n=6 for both groups.
*Significantly different (Po0.05) from OVX.
bSignificantly different from D+OVX.
cSignificantly different from D+OVX as determined by one-way ANOVA followed by Tukey’s multiple-comparisons test.
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Figure 3 | Immunoblotting for the NHE3 and the NaPi-2. (a) Example immunoblots for cortex and outer medulla, probed with polyclonal
antibodies against either NHE3 or NaPi-2, as indicated on the left of the blots. For each blot, lanes are loaded with rats’ samples 1–6 from each
treatment group, left to right (n¼ 6/group), with an equal amount of total protein loaded in each lane. Coomassie-stained loading gels
confirmed equality of loading. (b–d) Corresponding densitometry summaries with two- and one-way P-values provided. Mean band densities
plus standard error of measurements for each treatment are plotted. *Indicates a significant (Po0.05) difference from the OVX group, as
determined by one-way ANOVA followed by Tukey’s multiple-comparisons test. NHE3 abundance in the cortex was significantly higher in the
DþOVX group relative to the OVX group. Two-way ANOVA of NaPi-2 in the cortex revealed a significant decrease in diabetic rats.
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Figure 4a and c). Furthermore, NCC was either unchanged
(cortex) or modestly decreased by diabetes (whole kidney).
Diabetes reduced both whole-kidney (Table 3) and cortex
abundance of the a- as well as the b-subunit of the ENaC
(Figure 5a, b, and e). E2 was able to restore the b-subunit to
the OVX (nondiabetic) level. Diabetes also modestly reduced
the inner and outer medullary abundances of a-ENaC (Figure
5a, c, and d). In contrast, b-ENaC was increased by diabetes
in the medulla (Figure 5a, f, and g). Finally, E2 administration
to nondiabetic rats resulted in decreased outer medullary
b-ENaC abundance (Figure 5a and f) and increased a-ENaC
in the cortex (Figure 5a and b).
In the cortex and whole-kidney homogenates, of diabetic
animals, we found a significant increase in the major band
associated with g-ENaC (85 kDa, Table 3, Figure 6a and b).
This band was analyzed separately from the ‘70-kDa band’,
due to the fact that these two bands or band regions are
differentially regulated.12,13 Vasopressin has been shown to
increase the density of the 85-kDa band.12 The 70-kDa band
is actually a broad series of diffuse bands, the chemical nature
of which is not known. This band region has been
demonstrated to be increased by aldosterone infusion or
feeding of a low-NaCl diet.13 In the outer medulla (Figure 6a
and c), E2 replacement to non-D rats resulted in a trend for
lower expression of this band (similar to b-ENaC and
NKCC2). Cortical (Figure 6a and e) and whole-kidney
(Table 3) abundance of a-1-Na–K–ATPase was increased by
diabetes. Similar to several other proteins, the outer med-
ullary abundance of a-1-Na–K–ATPase was decreased by E2
(Figure 6a and f).
Owing to the high variability in the degree of diabetic
severity in the diabetic groups, we also correlated renal
protein abundances in the diabetic groups to urinary
albumin excretion in the final collection, as a marker of the
degree of renal damage (Figure 7). The three proteins in
which renal abundance (whole kidney) correlated most
closely with albumin excretion are shown. The abundance
of NKCC2 showed a significant positive correlation, whereas
a- and b-ENaC were significantly negatively correlated to
urinary albumin levels.
DISCUSSION
Poorly controlled, DM is associated with a fairly substantial
diuresis and natriuresis, as well as, eventually, the develop-
ment and progression of chronic renal disease. E2 and its
analogues have been shown by ourselves6 and others14,15 to
be protective against the progression of kidney disease. In this
report, our major findings included the following: (1) E2
replacement to diabetic rats normalized the abundance of
several major renal sodium transport proteins and channel
subunits, including the bumetanide-sensitive NKCC2, and
the a- and b-subunits of ENaC; (2) E2 replacement to
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Figure 4 | Immunoblotting for the sodium, potassium, two chloride cotransporters (NKCC2), and the sodium, chloride cotransporter
(NCC). (a) Example immunoblots for the cortex and outer medulla, probed with polyclonal antibodies against either NKCC2 or NCC, as
indicated on the left of the blots. For each blot, lanes are loaded with rats’ samples 1–6 from each treatment group, left to right (n¼ 6/group),
with an equal amount of total protein loaded in each lane. Coomassie-stained loading gels confirmed equality of loading. (b–d) Corresponding
densitometry summaries with two- and one-way P-values provided. Mean band densities plus standard error of measurements for each
treatment are plotted. t indicates a significant (Po0.05) difference from OVXþ E2 as determined by one-way ANOVA followed by Tukey’s
multiple-comparisons test. NKCC2 in the outer medulla was significantly greater in the DþOVX group relative to the OVXþ E2 group. Two-way
ANOVA of NKCC2 in the outer medulla revealed a significant increase due to diabetes and a significant decrease due to estrogen.
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nondiabetic OVX rats independently affected the abundance
of several renal sodium transport proteins; in particular, it
seemed to reduce the relative abundance of both thick
ascending limb- and collecting duct-associated transport or
channel proteins in the outer medulla of the kidney; (3) E2
replacement to streptozotocin-induced diabetic female, OVX
rats attenuated the severity of the diabetes, as determined by
a lessening of hyperglycemia and hyperalbuminuria; and
(4) diabetic rats had reduced final circulating levels of
estradiol despite a similar replacement protocol for diabetic
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Figure 5 | Immunoblotting for the a- and b-subunits of ENaC. (a) Example immunoblots for cortex, outer, and inner medulla, probed with
polyclonal antibodies against either a- or b-ENaC, as indicated on the left of the blots. For each blot, lanes are loaded with rats’ samples 1–6
from each treatment group, left to right (n¼ 6/group) with an equal amount of total protein loaded in each lane. Coomassie-stained loading
gels confirmed equality of loading. (b–g) Corresponding densitometry summaries with two- and one-way P-values provided. Mean band
densities plus standard error of measurements for each treatment are plotted. * indicates a significant (Po0.05) difference from OVX and t
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In addition, estrogen increased b-ENaC in the cortex, but decreased it in the outer medulla.
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Figure 6 | Immunoblotting for the c-subunit of ENaC and a-1-Na–K–ATPase. (a) Example immunoblots for the cortex, outer, and inner
medulla, probed with antibodies against either g-ENaC or a-1-Na–K–ATPase, as indicated on the left of the blots. For each blot, lanes are loaded
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Estrogen increased g-ENaC (85-kDa band) in the cortex.
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and nondiabetic, OVX rats. In the remainder of the
Discussion, we elaborate on these findings.
The administration of E2 to the D rats prevented what
appears to be pathologically induced downregulation of
select cortical collecting duct proteins, for example, the
a- and b-subunits of the ENaC. The pattern of changes for
these proteins, with diabetes, is different from what was
previously found1 in the short-term, streptozotocin-treated
rats, in which both a- and b-ENaC were increased in
abundance after 4–14 days of DM. However, it agreed with
the marked downregulation we observed for a-ENaC
abundance in obese Zucker rats with chronic, progressive
type II diabetes.5 This suggests that rats with more acute
hyperglycemia (4–14 days) are able to compensate for the
natriuretic loss of sodium via increased aldosterone and
vasopressin activity to increase the abundance, and pre-
sumably the activity of sensitive proteins. However, with
more chronic hyperglycemia (in this study 12 weeks), rats
may lose their ability to compensate for sodium losses by
upregulation of antinatriuretic hormones and proteins, and
thus ‘decompensate’ with regard to their ability to upregulate
these particular collecting-duct-associated proteins, which
are so important in day-to-day sodium balance. An inability
to respond to the elevated levels of circulating antinatriuretic
hormones appropriately might have contributed to the
relatively lower plasma sodium levels observed in the diabetic
rats. In agreement with decompensation, as determined by an
inability to respond appropriately to aldosterone, urinary
potassium to sodium ratio (an index of aldosterone activity)
was significantly decreased in diabetic rats despite signifi-
cantly higher levels of circulating plasma aldosterone levels.
E2 replacement markedly attenuated the above negative
effects of diabetes on sodium handling.
However, in agreement with our previous study1 examin-
ing the short-term effects of streptozotocin-induced diabetes
on young male rats, the abundance of the bumetanide-
sensitive NKCC2 was increased by diabetes and this increase
was attenuated by E2 replacement. This does not agree with
our findings in the type II, obese Zucker rats, where this
protein was also markedly downregulated in diabetes.5 The
mechanisms underlying the differences between the two
models are not clear, but likely independent of hyperglyce-
mia, since glucose levels were elevated in both studies. One
difference between the two models is the level of circulating
insulin, which is high in the obese Zucker rat, but low in the
streptozotocin-treated rat. Recently, we16 showed that
fructose-fed rats (a model of insulin resistance and
hyperinsulinemia) had decreased the whole-kidney abun-
dance of NKCC2. Also, vasopressin levels were elevated in
this study of type I diabetes, but not in our obese Zucker rats.
We have previously shown17 that vasopressin upregulates the
abundance of this protein.
Furthermore, we found that E2 replacement to nondiabetic
OVX rats resulted in the downregulation of at least three
sodium transport proteins in the outer medullary homo-
genates. The inner stripe of the outer medulla is composed of
both thick ascending limbs and collecting ducts, which
express the various proteins that we probed for. Decreased
abundance of NKCC2 and a-1-Na–K–ATPase, as well as a
trend for decreased NHE3 abundance with E2 replacement,
might suggest decreased sodium transport capacity of the TAL
in E2-replaced rats. This might impact on the urinary
concentrating capacity or possibly blood pressure in these
rats. E2 replacement has been associated with reduced blood
pressure in OVX female rats18 and increased NKCC2 activity
or expression has been associated with hypertension in
rats.19,20 In addition, we also found decreased abundance of
one collecting-duct-associated protein, that is, the b-subunit
of ENaC, in the outer medullary homogenates from
E2-replaced, nondiabetic rats relative to OVX.
Our finding of attenuation of the severity of renal
pathology associated with diabetes in OVX female rats
replaced with E2 was not an entirely new observation.
Previously,6 we showed a diminishment in albuminuria and
tubular interstitial fibrosis in diabetic E2-replaced female rats
relative to OVX female rats. In those studies, however, we did
not observe any significant difference in final blood glucose
levels, suggesting that the protective effect of E2 was
independent of hyperglycemia. In the current study, blood
glucose levels were clearly lower in rats treated chronically
(every fourth day to mimic the normal estrus cycle), with a
physiological level of E2. We speculate that E2 may either be
stimulating remnant pancreatic b-cell activity or decreasing
the destruction of b-cells by streptozotocin, possibly by
reducing inflammation. The reason for the difference
between our two studies is not clear. One difference was
that in the previous study E2 was replaced via an implanted
pellet (rather than every fourth day injections), so that levels
were physiological, but not cyclical. Perhaps the cyclical
nature of the replacement in the current study afforded
greater protection.
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Figure 7 | Correlation of immunoblotting densitometry for
(a) NKCC2, (b) a-ENaC, and (c) b-ENaC with urinary albumin
excretion in diabetic rats. NKCC2 abundance was significantly
(Po0.05) positively correlated to urinary albumin excretion, whereas
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A protective effect of E2 on b-cell viability is feasible based
on the work of other investigators. The presence of a
nonclassical estrogen receptor in pancreatic b- as well as
a-cells has been reported.21,22 These investigators have also
found that treatment of pancreatic b-cells with estrogen
enhanced insulin release in response to glucose.23 In addition,
Eckhoff et al.24 propose an anti-inflammatory role for E2.
They found higher pancreatic islet cell functionality in vivo
and in vitro in cells recovered from brain-dead pancreatic
donor rats treated intravenously with E2, which correlated
with a reduction in key inflammatory cytokines, that is,
tumor necrosis factor-a, interleukin-1-b, and interleukin-6.
This agrees with our previous work6 in which we found
decreased transforming growth factor-beta (TGF-b) in the
kidney from E2-replaced rats relative to OVX rats.
Furthermore, DþOVXþ E2 rats had significantly lower
measurable levels of final plasma estradiol than OVXþ E2
despite a similar replacement protocol. This was also different
from what we had observed previously with the pelleted-E2
replacement, where there were no differences in final
estradiol levels between OVXþ E2 diabetic and nondiabetic
rats. Therefore, the mode or timing of the E2 replacement
may be important. Previously,6 we reported that ovary-intact,
diabetic female rats had lower circulating estradiol levels than
nondiabetic rats. Decreased ovarian function may have
played a role in those studies, as decreased aromatase activity
(converts androgen to estrogen) has been reported in women
with type II diabetes25 and women with type I diabetes have
been reported to reach menopause more rapidly.26 However,
in the current study, rats were OVX and replaced with a
controlled dose of E2; yet, a decrease in the final measured
plasma level of estradiol was found, suggesting that an
additional mechanism, such as a shorter half-life of
circulating estradiol in diabetes, needs to be considered.
Other groups27,28 have reported a blunting of estrogen’s
protective effects during diabetes in OVX, E2-replaced rats;
however, few have actually measured the level of plasma
estradiol after replacing.
Overall, E2 replacement to diabetic rats reduced the
severity of the diabetes. In addition, it attenuated many of the
diabetically induced changes in renal sodium handling, as
well as the regulation of key sodium transporters and channel
subunits. Additional studies will be needed to ascertain
whether there is still relative preservation of renal sodium
reabsorptive proteins in estrogen-replete, but equally diabetic
rats, as well as to determine the impact of hyperglycemia or
diabetes when estrogen levels are clearly not different.
Nonetheless, these findings suggest a fundamental need to
assess estrogen status in diabetic women.
MATERIALS AND METHODS
Animals and study design
In all, 24 female Sprague–Dawley rats weighing B210 g were
obtained from Taconic Farms (Germantown, NY, USA). After an
overnight fast following a 5-day equilibration period, all rats were
anesthetized with isoflurane (IsoFlos, Abbot Laboratories, North
Chicago, IL, USA) and a bilateral ovariectomy (OVX) was
performed. To induce type I DM (D), streptozotocin (55 mg/kg
bw, dissolved in 0.2 ml of 0.1 M citric acid) was injected
intraperitoneally into half of the rats (n¼ 12), which were randomly
selected. The remaining rats (n¼ 12) received intraperitoneal
injections of the vehicle. Rats were further randomly subdivided
(n¼ 6/group) into those that were to be E2 replaced (E2) and those
that were not. E2 (5 mg, E8875 Sigma Chemical CO, St Louis, MO,
USA) in peanut oil was injected subcutaneously every fourth day to
the two appropriate replacement groups. All animals had free access
to water and phytoestrogen-free chow (Harlan-Teklad, Madison,
WI, USA) for 12 weeks.
In the D groups, blood glucose levels were measured twice weekly
by glucometer (TheraSense, Freestyle, Alameda, CA, USA) reading
of tail blood. If the level was higher than 25 mmol/l, insulin glargine
(2–6 U, Lantus, Aventis Pharmaceuticals Inc., Kansas City, MO,
USA) was administered (at most every other day) so that rats did
not lose weight and survived the 12-week study. Rats were singly
housed in Nalgenes metabolic cages (Harvard Apparatus, Holliston,
MA, USA) for 24 h to facilitate urine collection during the third,
sixth, ninth, and 12th weeks of the study.
Urine was analyzed for albumin (ELISA Assay, Nephrat II
albumin Kit, Exocell, Philadelphia, PA, USA), sodium and
potassium (ion-selective electrode system, EL-ISE Electrolyte
System, Beckman Instruments Inc., Brea, CA, USA), creatinine
(Jaffe rate method, Creatinine Analyzer 2, Beckmann Diagnostic
Systems Group, Brea, CA, USA), and osmolality (freezing point
depression, Advanced Instruments, Norwood, MA, USA). All
animals were maintained at all times under conditions and protocols
approved by the Georgetown University Animal Care and Use
Committee, an American Association for Accreditation of Labo-
ratory Animal Care-sanctioned facility.
Rats were euthanized by decapitation and trunk blood collected
into both heparinized and K3-ethylene diamine tetraacetate tubes
(Vacutainer, Becton-Dickinson, Franklin Lakes, NJ, USA). Both
kidneys were rapidly removed for preparation of samples for
immunoblotting. Whole left kidneys and right kidney cortex (CTX),
inner stripe of the outer medulla, and inner medulla were
homogenized and aliquots of whole homogenates prepared for
immunoblotting as described previously.29,30
Plasma analyses
Whole blood was centrifuged at 3000 rotations per minute (Sorvall
RT 6000 D, Sorvall, Newtown, CT, USA) at 41C for 20 min to
separate plasma. Plasma aldosterone, vasopressin, and renin levels
were measured by radioimmunoassay according to previously
published methods.1,31 Likewise, plasma estradiol levels were
measured by radioimmunoassay (Coat-a-Counts kit, Diagnostic
Products Company, Los Angeles, CA, USA). Plasma was also
analyzed for creatinine, sodium, and potassium according to the
methods described above. Plasma fructosamine, as an index of long-
term diabetes management, was analyzed via an enzymatic,
colorimetric kit (Fructosamine Enzymatic Assay, Ploymedco
GLyca-Direct, Polymedco Inc., Cortlandt Manor, NY, USA).
Immunoblotting
Before immunoblotting, all sample sets were loaded onto precast
12% polyacrylamide (BioRad, Hercules, CA, USA) gels and stained
with Coomassie brilliant blue in order to assess the quality of the
proteins by sharpness of the bands, and to determine if protein
measurements were accurate, as described previously.12,30 For
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immunoblotting, an equal amount of total protein (5–30 mg) from
each sample was loaded into individual lanes of minigels of 7, 10, or
12% polyacrylamide. Immunoblotting protocols have been de-
scribed previously.12 We used our own peptide-derived, polyclonal
antibodies against NCC, a-, b-, and g-ENaC, which have been
characterized previously.31 Polyclonal antibodies against the bumeta-
nide-sensitive NKCC2 were a kind gift of Dr Janet Klein (Emory
University, Atlanta, GA, USA). Commercial polyclonal antibodies
were used for NHE3 and NaPi-2 obtained from Alpha Diagnostic
International (San Antonio, TX, USA). The mouse monoclonal
antibody to a-1-Na–K–ATPase was obtained from Upstate Biotech-
nology (Lake Placid, NY, USA).
Statistics
To determine the overall effects of E2 replacement and diabetes on
variables of interest, data were analyzed by two-way (E2D)
ANOVA. In addition, in order to determine the differences between
individual pairs of means, data were also analyzed by one-way
ANOVA followed by Tukey’s multiple-comparisons test if the
P-value was o0.05. If data were nonparametric, for example, E2
or glucose levels, not normally distributed, or variances were
different, we used Kruskal–Wallis ANOVA on ranks, followed by
Dunn’s multiple-comparisons test (Sigma Stat, Chicago, IL, USA).
Po0.05 was considered significant.
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